ID   GABR2_HUMAN             Reviewed;         941 AA.
AC   O75899; O75974; O75975; Q5VXZ2; Q8WX04; Q9P1R2; Q9UNR1; Q9UNS9;
DT   11-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1998, sequence version 1.
DT   07-APR-2021, entry version 198.
DE   RecName: Full=Gamma-aminobutyric acid type B receptor subunit 2;
DE            Short=GABA-B receptor 2;
DE            Short=GABA-B-R2;
DE            Short=GABA-BR2;
DE            Short=GABABR2;
DE            Short=Gb2;
DE   AltName: Full=G-protein coupled receptor 51;
DE   AltName: Full=HG20;
DE   Flags: Precursor;
GN   Name=GABBR2; Synonyms=GPR51, GPRC3B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBUNIT, INTERACTION WITH GABBR1, AND
RP   SUBCELLULAR LOCATION.
RC   TISSUE=Cerebellum {ECO:0000303|PubMed:9872316};
RX   PubMed=9872316; DOI=10.1038/25354;
RA   White J.H., Wise A., Main M.J., Green A., Fraser N.J., Disney G.H.,
RA   Barnes A.A., Emson P., Foord S.M., Marshall F.H.;
RT   "Heterodimerization is required for the formation of a functional GABA(B)
RT   receptor.";
RL   Nature 396:679-682(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Fetal brain {ECO:0000303|PubMed:10087195};
RX   PubMed=10087195; DOI=10.1006/geno.1998.5706;
RA   Ng G.Y.K., McDonald T., Bonnert T., Rigby M., Heavens R., Whiting P.,
RA   Chateauneuf A., Coulombe N., Kargman S., Caskey T., Evans J.F.,
RA   O'Neill G.P., Liu Q.;
RT   "Cloning of a novel G-protein-coupled receptor GPR 51 resembling GABAB
RT   receptors expressed predominantly in nervous tissues and mapped proximal to
RT   the hereditary sensory neuropathy type 1 locus on chromosome 9.";
RL   Genomics 56:288-295(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, AND VARIANTS PHE-628 AND ALA-869.
RC   TISSUE=Brain {ECO:0000303|PubMed:10328880};
RX   PubMed=10328880; DOI=10.1006/mcne.1999.0741;
RA   Martin S.C., Russek S.J., Farb D.H.;
RT   "Molecular identification of the human GABABR2: cell surface expression and
RT   coupling to adenylyl cyclase in the absence of GABABR1.";
RL   Mol. Cell. Neurosci. 13:180-191(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Brain {ECO:0000303|PubMed:10727622};
RX   PubMed=10727622; DOI=10.1016/s0006-8993(00)01958-2;
RA   Clark J.A., Mezey E., Lam A.S., Bonner T.I.;
RT   "Distribution of the GABA(B) receptor subunit gb2 in rat CNS.";
RL   Brain Res. 860:41-52(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Liu M., Parker R., McCrea K., Watson J., Baker E., Sutherland G.,
RA   Herzog H.;
RT   "Cloning and characterization of a novel human GABA-B receptor subtype with
RT   high affinity for GABA and low affinity for baclofen.";
RL   Submitted (NOV-1998) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Hippocampus {ECO:0000303|Ref.6};
RA   Borowsky B., Laz T., Gerald C.;
RL   Submitted (JAN-1999) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 14-941.
RC   TISSUE=Hippocampus {ECO:0000303|PubMed:15489334};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   FUNCTION.
RX   PubMed=10075644; DOI=10.1074/jbc.274.12.7607;
RA   Ng G.Y.K., Clark J., Coulombe N., Ethier N., Hebert T.E., Sullivan R.,
RA   Kargman S., Chateauneuf A., Tsukamoto N., McDonald T., Whiting P.,
RA   Mezey E., Johnson M.P., Liu Q., Kolakowski L.F. Jr., Evans J.F.,
RA   Bonner T.I., O'Neill G.P.;
RT   "Identification of a GABAB receptor subunit, gb2, required for functional
RT   GABAB receptor activity.";
RL   J. Biol. Chem. 274:7607-7610(1999).
RN   [10]
RP   FUNCTION, INTERACTION WITH GABBR1, TISSUE SPECIFICITY, AND DOMAIN.
RX   PubMed=9872744; DOI=10.1126/science.283.5398.74;
RA   Kuner R., Koehr G., Gruenewald S., Eisenhardt G., Bach A., Kornau H.-C.;
RT   "Role of heteromer formation in GABAB receptor function.";
RL   Science 283:74-77(1999).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH GABBR1.
RX   PubMed=10906333; DOI=10.1074/jbc.m005333200;
RA   Schwarz D.A., Barry G., Eliasof S.D., Petroski R.E., Conlon P.J.,
RA   Maki R.A.;
RT   "Characterization of gamma-aminobutyric acid receptor GABAB(1e), a GABAB(1)
RT   splice variant encoding a truncated receptor.";
RL   J. Biol. Chem. 275:32174-32181(2000).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH GABBR1.
RX   PubMed=10773016;
RA   Sullivan R., Chateauneuf A., Coulombe N., Kolakowski L.F. Jr.,
RA   Johnson M.P., Hebert T.E., Ethier N., Belley M., Metters K., Abramovitz M.,
RA   O'Neill G.P., Ng G.Y.K.;
RT   "Coexpression of full-length gamma-aminobutyric acid(B) (GABA(B)) receptors
RT   with truncated receptors and metabotropic glutamate receptor 4 supports the
RT   GABA(B) heterodimer as the functional receptor.";
RL   J. Pharmacol. Exp. Ther. 293:460-467(2000).
RN   [13]
RP   VARIANT NDPLHS THR-567.
RX   PubMed=26740508; DOI=10.1136/jmedgenet-2015-103568;
RA   Lopes F., Barbosa M., Ameur A., Soares G., de Sa J., Dias A.I.,
RA   Oliveira G., Cabral P., Temudo T., Calado E., Cruz I.F., Vieira J.P.,
RA   Oliveira R., Esteves S., Sauer S., Jonasson I., Syvaenen A.C.,
RA   Gyllensten U., Pinto D., Maciel P.;
RT   "Identification of novel genetic causes of Rett syndrome-like phenotypes.";
RL   J. Med. Genet. 53:190-199(2016).
RN   [14]
RP   FUNCTION, INTERACTION WITH GABBR1, SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=15617512; DOI=10.1042/bj20041435;
RA   Villemure J.F., Adam L., Bevan N.J., Gearing K., Chenier S., Bouvier M.;
RT   "Subcellular distribution of GABA(B) receptor homo- and hetero-dimers.";
RL   Biochem. J. 388:47-55(2005).
RN   [15]
RP   FUNCTION, SUBUNIT, AND INTERACTION WITH GABBR1.
RX   PubMed=18165688; DOI=10.1074/jbc.m705202200;
RA   Nomura R., Suzuki Y., Kakizuka A., Jingami H.;
RT   "Direct detection of the interaction between recombinant soluble
RT   extracellular regions in the heterodimeric metabotropic gamma-aminobutyric
RT   acid receptor.";
RL   J. Biol. Chem. 283:4665-4673(2008).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.38 ANGSTROMS) OF 42-466, PARTIAL PROTEIN SEQUENCE,
RP   FUNCTION, INTERACTION WITH GABBR1, MUTAGENESIS OF TYR-118, GLYCOSYLATION AT
RP   ASN-90; ASN-389; ASN-404 AND ASN-453, AND DISULFIDE BONDS.
RX   PubMed=22660477; DOI=10.1038/nn.3133;
RA   Geng Y., Xiong D., Mosyak L., Malito D.L., Kniazeff J., Chen Y.,
RA   Burmakina S., Quick M., Bush M., Javitch J.A., Pin J.P., Fan Q.R.;
RT   "Structure and functional interaction of the extracellular domain of human
RT   GABA(B) receptor GBR2.";
RL   Nat. Neurosci. 15:970-978(2012).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 42-466 IN COMPLEXES WITH GABBR1;
RP   AGONISTS AND ANTAGONISTS, FUNCTION, SUBUNIT, GLYCOSYLATION AT ASN-404, AND
RP   DISULFIDE BOND.
RX   PubMed=24305054; DOI=10.1038/nature12725;
RA   Geng Y., Bush M., Mosyak L., Wang F., Fan Q.R.;
RT   "Structural mechanism of ligand activation in human GABA(B) receptor.";
RL   Nature 504:254-259(2013).
RN   [18]
RP   INVOLVEMENT IN DEE59, AND VARIANT DEE59 TRP-693.
RX   PubMed=29100083; DOI=10.1016/j.ajhg.2017.09.008;
RG   Deciphering Developmental Disorders Study;
RA   Hamdan F.F., Myers C.T., Cossette P., Lemay P., Spiegelman D.,
RA   Laporte A.D., Nassif C., Diallo O., Monlong J., Cadieux-Dion M.,
RA   Dobrzeniecka S., Meloche C., Retterer K., Cho M.T., Rosenfeld J.A., Bi W.,
RA   Massicotte C., Miguet M., Brunga L., Regan B.M., Mo K., Tam C.,
RA   Schneider A., Hollingsworth G., FitzPatrick D.R., Donaldson A., Canham N.,
RA   Blair E., Kerr B., Fry A.E., Thomas R.H., Shelagh J., Hurst J.A.,
RA   Brittain H., Blyth M., Lebel R.R., Gerkes E.H., Davis-Keppen L., Stein Q.,
RA   Chung W.K., Dorison S.J., Benke P.J., Fassi E., Corsten-Janssen N.,
RA   Kamsteeg E.J., Mau-Them F.T., Bruel A.L., Verloes A., Ounap K.,
RA   Wojcik M.H., Albert D.V.F., Venkateswaran S., Ware T., Jones D., Liu Y.C.,
RA   Mohammad S.S., Bizargity P., Bacino C.A., Leuzzi V., Martinelli S.,
RA   Dallapiccola B., Tartaglia M., Blumkin L., Wierenga K.J., Purcarin G.,
RA   O'Byrne J.J., Stockler S., Lehman A., Keren B., Nougues M.C., Mignot C.,
RA   Auvin S., Nava C., Hiatt S.M., Bebin M., Shao Y., Scaglia F., Lalani S.R.,
RA   Frye R.E., Jarjour I.T., Jacques S., Boucher R.M., Riou E., Srour M.,
RA   Carmant L., Lortie A., Major P., Diadori P., Dubeau F., D'Anjou G.,
RA   Bourque G., Berkovic S.F., Sadleir L.G., Campeau P.M., Kibar Z.,
RA   Lafreniere R.G., Girard S.L., Mercimek-Mahmutoglu S., Boelman C.,
RA   Rouleau G.A., Scheffer I.E., Mefford H.C., Andrade D.M., Rossignol E.,
RA   Minassian B.A., Michaud J.L.;
RT   "High rate of recurrent de novo mutations in developmental and epileptic
RT   encephalopathies.";
RL   Am. J. Hum. Genet. 101:664-685(2017).
RN   [19]
RP   INVOLVEMENT IN NDPLHS, INVOLVEMENT IN DEE59, VARIANT NDPLHS THR-567,
RP   VARIANTS DEE59 ILE-695 AND ASN-705, CHARACTERIZATION OF VARIANT NDPLHS
RP   THR-567, AND CHARACTERIZATION OF VARIANTS DEE59 ILE-695 AND ASN-705.
RX   PubMed=28856709; DOI=10.1002/ana.25032;
RA   Yoo Y., Jung J., Lee Y.N., Lee Y., Cho H., Na E., Hong J., Kim E.,
RA   Lee J.S., Lee J.S., Hong C., Park S.Y., Wie J., Miller K., Shur N.,
RA   Clow C., Ebel R.S., DeBrosse S.D., Henderson L.B., Willaert R.,
RA   Castaldi C., Tikhonova I., Bilguevar K., Mane S., Kim K.J., Hwang Y.S.,
RA   Lee S.G., So I., Lim B.C., Choi H.J., Seong J.Y., Shin Y.B., Jung H.,
RA   Chae J.H., Choi M.;
RT   "GABBR2 mutations determine phenotype in rett syndrome and epileptic
RT   encephalopathy.";
RL   Ann. Neurol. 82:466-478(2017).
RN   [20]
RP   INVOLVEMENT IN NDPLHS, VARIANT NDPLHS THR-707, CHARACTERIZATION OF VARIANTS
RP   NDPLHS THR-567 AND THR-707, AND CHARACTERIZATION OF VARIANTS DEE59 ILE-695
RP   AND ASN-705.
RX   PubMed=29369404; DOI=10.1002/ana.25155;
RA   Vuillaume M.L., Jeanne M., Xue L., Blesson S., Denomme-Pichon A.S.,
RA   Alirol S., Brulard C., Colin E., Isidor B., Gilbert-Dussardier B.,
RA   Odent S., Parent P., Donnart A., Redon R., Bezieau S., Rondard P.,
RA   Laumonnier F., Toutain A.;
RT   "A novel mutation in the transmembrane 6 domain of GABBR2 leads to a Rett-
RT   like phenotype.";
RL   Ann. Neurol. 83:437-439(2018).
CC   -!- FUNCTION: Component of a heterodimeric G-protein coupled receptor for
CC       GABA, formed by GABBR1 and GABBR2 (PubMed:9872316, PubMed:9872744,
CC       PubMed:15617512, PubMed:18165688, PubMed:22660477, PubMed:24305054).
CC       Within the heterodimeric GABA receptor, only GABBR1 seems to bind
CC       agonists, while GABBR2 mediates coupling to G proteins
CC       (PubMed:18165688). Ligand binding causes a conformation change that
CC       triggers signaling via guanine nucleotide-binding proteins (G proteins)
CC       and modulates the activity of down-stream effectors, such as adenylate
CC       cyclase (PubMed:10075644, PubMed:10773016, PubMed:24305054). Signaling
CC       inhibits adenylate cyclase, stimulates phospholipase A2, activates
CC       potassium channels, inactivates voltage-dependent calcium-channels and
CC       modulates inositol phospholipid hydrolysis (PubMed:10075644,
CC       PubMed:9872744, PubMed:10906333, PubMed:10773016). Plays a critical
CC       role in the fine-tuning of inhibitory synaptic transmission
CC       (PubMed:9872744, PubMed:22660477). Pre-synaptic GABA receptor inhibits
CC       neurotransmitter release by down-regulating high-voltage activated
CC       calcium channels, whereas postsynaptic GABA receptor decreases neuronal
CC       excitability by activating a prominent inwardly rectifying potassium
CC       (Kir) conductance that underlies the late inhibitory postsynaptic
CC       potentials (PubMed:9872316, PubMed:10075644, PubMed:9872744,
CC       PubMed:22660477). Not only implicated in synaptic inhibition but also
CC       in hippocampal long-term potentiation, slow wave sleep, muscle
CC       relaxation and antinociception (Probable).
CC       {ECO:0000269|PubMed:10075644, ECO:0000269|PubMed:10328880,
CC       ECO:0000269|PubMed:15617512, ECO:0000269|PubMed:18165688,
CC       ECO:0000269|PubMed:22660477, ECO:0000269|PubMed:24305054,
CC       ECO:0000269|PubMed:9872316, ECO:0000269|PubMed:9872744, ECO:0000305}.
CC   -!- SUBUNIT: Heterodimer of GABBR1 and GABBR2 (PubMed:9872316,
CC       PubMed:9872744, PubMed:10906333, PubMed:10773016, PubMed:15617512,
CC       PubMed:18165688, PubMed:22660477, PubMed:24305054). Homodimers may
CC       form, but are inactive (PubMed:15617512). Interacts (via C-terminus)
CC       with ATF4 (via leucine zipper domain) (By similarity).
CC       {ECO:0000250|UniProtKB:Q9Z0U4, ECO:0000269|PubMed:10773016,
CC       ECO:0000269|PubMed:15617512, ECO:0000269|PubMed:18165688,
CC       ECO:0000269|PubMed:22660477, ECO:0000269|PubMed:24305054,
CC       ECO:0000269|PubMed:9872316, ECO:0000269|PubMed:9872744}.
CC   -!- INTERACTION:
CC       O75899; Q9UBS5: GABBR1; NbExp=4; IntAct=EBI-715469, EBI-724156;
CC       O75899; Q9UBS5-2: GABBR1; NbExp=6; IntAct=EBI-715469, EBI-16084001;
CC       O75899; P46459: NSF; NbExp=4; IntAct=EBI-715469, EBI-712251;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10328880,
CC       ECO:0000269|PubMed:15617512, ECO:0000269|PubMed:9872316}; Multi-pass
CC       membrane protein {ECO:0000305}. Cell junction, synapse, postsynaptic
CC       cell membrane {ECO:0000250|UniProtKB:O88871}; Multi-pass membrane
CC       protein {ECO:0000305}. Note=Coexpression of GABBR1 and GABBR2 is
CC       required for GABBR1 maturation and transport to the plasma membrane. In
CC       contrast, GABBR2 does not depend on GABBR1 for transport to the cell
CC       membrane. {ECO:0000269|PubMed:15617512}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in brain, especially in cerebral
CC       cortex, thalamus, hippocampus, frontal, occipital and temporal lobe,
CC       occipital pole and cerebellum, followed by corpus callosum, caudate
CC       nucleus, spinal cord, amygdala and medulla (PubMed:10087195,
CC       PubMed:10328880, PubMed:10727622, PubMed:9872744). Weakly expressed in
CC       heart, testis and skeletal muscle (PubMed:10087195, PubMed:10727622).
CC       {ECO:0000269|PubMed:10087195, ECO:0000269|PubMed:10328880,
CC       ECO:0000269|PubMed:10727622, ECO:0000269|PubMed:9872744}.
CC   -!- DOMAIN: Alpha-helical parts of the C-terminal intracellular region
CC       mediate heterodimeric interaction with GABBR1.
CC       {ECO:0000305|PubMed:9872744}.
CC   -!- DISEASE: Neurodevelopmental disorder with poor language and loss of
CC       hand skills (NDPLHS) [MIM:617903]: An autosomal dominant disorder
CC       characterized by psychomotor developmental stagnation or regression.
CC       NDPLHS manifest in the first years of life as loss of purposeful hand
CC       movements, loss of language, and intellectual disability.
CC       {ECO:0000269|PubMed:26740508, ECO:0000269|PubMed:28856709,
CC       ECO:0000269|PubMed:29369404}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Developmental and epileptic encephalopathy 59 (DEE59)
CC       [MIM:617904]: A form of epileptic encephalopathy, a heterogeneous group
CC       of severe childhood onset epilepsies characterized by refractory
CC       seizures, neurodevelopmental impairment, and poor prognosis.
CC       Development is normal prior to seizure onset, after which cognitive and
CC       motor delays become apparent. DEE59 is an autosomal dominant condition
CC       characterized by onset of refractory seizures in early infancy.
CC       {ECO:0000269|PubMed:28856709, ECO:0000269|PubMed:29100083,
CC       ECO:0000269|PubMed:29369404}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 3 family. GABA-B
CC       receptor subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH35071.2; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ012188; CAA09942.1; -; mRNA.
DR   EMBL; AF069755; AAC99345.1; -; mRNA.
DR   EMBL; AF099033; AAD45867.1; -; mRNA.
DR   EMBL; AF056085; AAC63228.1; -; mRNA.
DR   EMBL; AF095784; AAD30389.1; -; mRNA.
DR   EMBL; AF074483; AAD03336.1; -; mRNA.
DR   EMBL; AL445495; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL353782; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL356282; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL591502; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC035071; AAH35071.2; ALT_INIT; mRNA.
DR   CCDS; CCDS6736.1; -.
DR   RefSeq; NP_005449.5; NM_005458.7.
DR   PDB; 4F11; X-ray; 2.38 A; A=42-466.
DR   PDB; 4F12; X-ray; 3.02 A; A=42-466.
DR   PDB; 4MQE; X-ray; 2.35 A; B=42-466.
DR   PDB; 4MQF; X-ray; 2.22 A; B=42-466.
DR   PDB; 4MR7; X-ray; 2.15 A; B=42-466.
DR   PDB; 4MR8; X-ray; 2.15 A; B=42-466.
DR   PDB; 4MR9; X-ray; 2.35 A; B=42-466.
DR   PDB; 4MRM; X-ray; 2.86 A; B=42-466.
DR   PDB; 4MS1; X-ray; 2.25 A; B=42-466.
DR   PDB; 4MS3; X-ray; 2.50 A; B=42-466.
DR   PDB; 4MS4; X-ray; 1.90 A; B=42-466.
DR   PDB; 4PAS; X-ray; 1.62 A; B=779-819.
DR   PDB; 6M8R; X-ray; 3.20 A; K/L=876-913.
DR   PDB; 6OCP; X-ray; 2.35 A; P/Q/R=895-909.
DR   PDB; 6UO8; EM; 3.63 A; B=41-819.
DR   PDB; 6UO9; EM; 4.80 A; B=41-819.
DR   PDB; 6UOA; EM; 6.30 A; B=41-819.
DR   PDB; 6VJM; EM; 3.97 A; B=41-819.
DR   PDB; 6W2X; EM; 3.60 A; B=42-941.
DR   PDB; 6WIV; EM; 3.30 A; B=1-819.
DR   PDB; 7C7Q; EM; 3.00 A; B=41-780.
DR   PDB; 7C7S; EM; 2.90 A; B=41-819.
DR   PDB; 7CA3; EM; 4.50 A; B=1-787.
DR   PDB; 7CA5; EM; 7.60 A; B=1-787.
DR   PDB; 7CUM; EM; 3.52 A; B=1-787.
DR   PDBsum; 4F11; -.
DR   PDBsum; 4F12; -.
DR   PDBsum; 4MQE; -.
DR   PDBsum; 4MQF; -.
DR   PDBsum; 4MR7; -.
DR   PDBsum; 4MR8; -.
DR   PDBsum; 4MR9; -.
DR   PDBsum; 4MRM; -.
DR   PDBsum; 4MS1; -.
DR   PDBsum; 4MS3; -.
DR   PDBsum; 4MS4; -.
DR   PDBsum; 4PAS; -.
DR   PDBsum; 6M8R; -.
DR   PDBsum; 6OCP; -.
DR   PDBsum; 6UO8; -.
DR   PDBsum; 6UO9; -.
DR   PDBsum; 6UOA; -.
DR   PDBsum; 6VJM; -.
DR   PDBsum; 6W2X; -.
DR   PDBsum; 6WIV; -.
DR   PDBsum; 7C7Q; -.
DR   PDBsum; 7C7S; -.
DR   PDBsum; 7CA3; -.
DR   PDBsum; 7CA5; -.
DR   PDBsum; 7CUM; -.
DR   SMR; O75899; -.
DR   BioGRID; 114938; 10.
DR   ComplexPortal; CPX-2955; GABA-B receptor complex.
DR   CORUM; O75899; -.
DR   DIP; DIP-42851N; -.
DR   IntAct; O75899; 7.
DR   MINT; O75899; -.
DR   STRING; 9606.ENSP00000259455; -.
DR   BindingDB; O75899; -.
DR   ChEMBL; CHEMBL5034; -.
DR   DrugBank; DB08891; Arbaclofen.
DR   DrugBank; DB08892; Arbaclofen Placarbil.
DR   DrugBank; DB00181; Baclofen.
DR   DrugBank; DB02530; gamma-Aminobutyric acid.
DR   DrugBank; DB05010; SGS-742.
DR   DrugCentral; O75899; -.
DR   GuidetoPHARMACOLOGY; 241; -.
DR   TCDB; 9.A.14.15.1; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; O75899; 5 sites.
DR   iPTMnet; O75899; -.
DR   PhosphoSitePlus; O75899; -.
DR   BioMuta; GABBR2; -.
DR   EPD; O75899; -.
DR   MassIVE; O75899; -.
DR   PaxDb; O75899; -.
DR   PeptideAtlas; O75899; -.
DR   PRIDE; O75899; -.
DR   ProteomicsDB; 50252; -.
DR   ABCD; O75899; 2 sequenced antibodies.
DR   Antibodypedia; 2939; 568 antibodies.
DR   DNASU; 9568; -.
DR   Ensembl; ENST00000259455; ENSP00000259455; ENSG00000136928.
DR   GeneID; 9568; -.
DR   KEGG; hsa:9568; -.
DR   UCSC; uc004ays.4; human.
DR   CTD; 9568; -.
DR   DisGeNET; 9568; -.
DR   GeneCards; GABBR2; -.
DR   HGNC; HGNC:4507; GABBR2.
DR   HPA; ENSG00000136928; Tissue enriched (brain).
DR   MalaCards; GABBR2; -.
DR   MIM; 607340; gene.
DR   MIM; 617903; phenotype.
DR   MIM; 617904; phenotype.
DR   neXtProt; NX_O75899; -.
DR   OpenTargets; ENSG00000136928; -.
DR   Orphanet; 3095; Atypical Rett syndrome.
DR   PharmGKB; PA28896; -.
DR   VEuPathDB; HostDB:ENSG00000136928.5; -.
DR   eggNOG; KOG1055; Eukaryota.
DR   GeneTree; ENSGT00940000155783; -.
DR   HOGENOM; CLU_005240_0_0_1; -.
DR   InParanoid; O75899; -.
DR   OMA; LLKHYHW; -.
DR   OrthoDB; 590810at2759; -.
DR   PhylomeDB; O75899; -.
DR   TreeFam; TF313965; -.
DR   PathwayCommons; O75899; -.
DR   Reactome; R-HSA-1296041; Activation of G protein gated Potassium channels.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-420499; Class C/3 (Metabotropic glutamate/pheromone receptors).
DR   Reactome; R-HSA-977444; GABA B receptor activation.
DR   Reactome; R-HSA-997272; Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits.
DR   BioGRID-ORCS; 9568; 3 hits in 988 CRISPR screens.
DR   ChiTaRS; GABBR2; human.
DR   GeneWiki; GABBR2; -.
DR   GenomeRNAi; 9568; -.
DR   Pharos; O75899; Tclin.
DR   PRO; PR:O75899; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; O75899; protein.
DR   Bgee; ENSG00000136928; Expressed in primary visual cortex and 171 other tissues.
DR   ExpressionAtlas; O75899; baseline and differential.
DR   Genevisible; O75899; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0038039; C:G protein-coupled receptor heterodimeric complex; IPI:UniProtKB.
DR   GO; GO:1902710; C:GABA receptor complex; IDA:CAFA.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004965; F:G protein-coupled GABA receptor activity; TAS:ProtInc.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:CAFA.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; IBA:GO_Central.
DR   GO; GO:0007268; P:chemical synaptic transmission; TAS:ProtInc.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007214; P:gamma-aminobutyric acid signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007194; P:negative regulation of adenylate cyclase activity; TAS:ProtInc.
DR   GO; GO:0150099; P:neuron-glial cell signaling; ISS:ARUK-UCL.
DR   GO; GO:1901381; P:positive regulation of potassium ion transmembrane transport; TAS:Reactome.
DR   InterPro; IPR001828; ANF_lig-bd_rcpt.
DR   InterPro; IPR041689; GBR2_CC.
DR   InterPro; IPR002455; GPCR3_GABA-B.
DR   InterPro; IPR000337; GPCR_3.
DR   InterPro; IPR017978; GPCR_3_C.
DR   InterPro; IPR017979; GPCR_3_CS.
DR   InterPro; IPR002457; GPCR_3_GABA_rcpt_B2.
DR   InterPro; IPR028082; Peripla_BP_I.
DR   PANTHER; PTHR10519; PTHR10519; 1.
DR   Pfam; PF00003; 7tm_3; 1.
DR   Pfam; PF01094; ANF_receptor; 1.
DR   Pfam; PF18455; GBR2_CC; 1.
DR   PRINTS; PR01178; GABAB2RECPTR.
DR   PRINTS; PR00248; GPCRMGR.
DR   SUPFAM; SSF53822; SSF53822; 1.
DR   PROSITE; PS00981; G_PROTEIN_RECEP_F3_3; 1.
DR   PROSITE; PS50259; G_PROTEIN_RECEP_F3_4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell junction; Cell membrane; Coiled coil;
KW   Direct protein sequencing; Disease variant; Disulfide bond; Epilepsy;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Mental retardation;
KW   Phosphoprotein; Postsynaptic cell membrane; Receptor; Reference proteome;
KW   Signal; Synapse; Transducer; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..41
FT                   /evidence="ECO:0000255"
FT   CHAIN           42..941
FT                   /note="Gamma-aminobutyric acid type B receptor subunit 2"
FT                   /id="PRO_0000012952"
FT   TOPO_DOM        42..483
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        484..504
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        505..522
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        523..543
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        544..551
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        552..572
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        573..597
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        598..618
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        619..654
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        655..675
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        676..691
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        692..712
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        713..720
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        721..741
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        742..941
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   COILED          781..819
FT                   /evidence="ECO:0000255"
FT   MOD_RES         776
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80T41"
FT   MOD_RES         779
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80T41"
FT   MOD_RES         819
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80T41"
FT   MOD_RES         884
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80T41"
FT   MOD_RES         893
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80T41"
FT   MOD_RES         913
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80T41"
FT   MOD_RES         916
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80T41"
FT   MOD_RES         920
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80T41"
FT   MOD_RES         924
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80T41"
FT   CARBOHYD        90
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:22660477"
FT   CARBOHYD        298
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        389
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:22660477"
FT   CARBOHYD        404
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:22660477,
FT                   ECO:0000269|PubMed:24305054"
FT   CARBOHYD        453
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:22660477"
FT   DISULFID        108..135
FT   DISULFID        237..266
FT   DISULFID        265..302
FT   VARIANT         163
FT                   /note="L -> P (in dbSNP:rs35449008)"
FT                   /id="VAR_049280"
FT   VARIANT         567
FT                   /note="A -> T (in NDPLHS; increased basal signaling
FT                   activity and only weak stimulation by GABA agonist; when
FT                   injected into Xenopus tadpoles, causes abnormal swimming
FT                   patterns and increased frequencies of seizure-like behavior
FT                   compared to wild-type-injected animals; no effect on cell
FT                   surface expression; dbSNP:rs922847767)"
FT                   /evidence="ECO:0000269|PubMed:26740508,
FT                   ECO:0000269|PubMed:28856709, ECO:0000269|PubMed:29369404"
FT                   /id="VAR_079029"
FT   VARIANT         628
FT                   /note="Y -> F"
FT                   /evidence="ECO:0000269|PubMed:10328880"
FT                   /id="VAR_010148"
FT   VARIANT         693
FT                   /note="G -> W (in DEE59; unknown pathological significance;
FT                   dbSNP:rs1554689320)"
FT                   /evidence="ECO:0000269|PubMed:29100083"
FT                   /id="VAR_080569"
FT   VARIANT         695
FT                   /note="S -> I (in DEE59; full signaling activity in the
FT                   absence of GABA agonist; when injected into Xenopus
FT                   tadpoles, causes abnormal swimming patterns and increased
FT                   frequencies of seizure-like behavior compared to wild-type-
FT                   injected animals; no effect on cell surface expression;
FT                   dbSNP:rs1554689319)"
FT                   /evidence="ECO:0000269|PubMed:28856709,
FT                   ECO:0000269|PubMed:29369404"
FT                   /id="VAR_080570"
FT   VARIANT         705
FT                   /note="I -> N (in DEE59; increased basal signaling activity
FT                   and no stimulation by GABA agonist; when injected into
FT                   Xenopus tadpoles, causes abnormal swimming patterns and
FT                   increased frequencies of seizure-like behavior compared to
FT                   wild-type-injected animals; no effect on cell surface
FT                   expression; dbSNP:rs1554689315)"
FT                   /evidence="ECO:0000269|PubMed:28856709,
FT                   ECO:0000269|PubMed:29369404"
FT                   /id="VAR_080571"
FT   VARIANT         707
FT                   /note="A -> T (in NDPLHS; increased basal signaling
FT                   activity and only weak stimulation by GABA agonist; no
FT                   effect on cell surface expression; dbSNP:rs1554689313)"
FT                   /evidence="ECO:0000269|PubMed:29369404"
FT                   /id="VAR_080572"
FT   VARIANT         869
FT                   /note="T -> A (in dbSNP:rs10985765)"
FT                   /evidence="ECO:0000269|PubMed:10328880"
FT                   /id="VAR_010149"
FT   MUTAGEN         118
FT                   /note="Y->A: Impairs interaction with GABBR1. Decreases
FT                   signaling via G-proteins."
FT                   /evidence="ECO:0000269|PubMed:22660477"
FT   CONFLICT        6
FT                   /note="S -> R (in Ref. 2; AAC99345)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        12
FT                   /note="P -> R (in Ref. 2; AAC99345)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        424
FT                   /note="G -> E (in Ref. 5; AAD30389)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        797
FT                   /note="R -> H (in Ref. 8; AAH35071)"
FT                   /evidence="ECO:0000305"
FT   STRAND          55..62
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   STRAND          66..68
FT                   /evidence="ECO:0007744|PDB:4MQE"
FT   HELIX           71..90
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   TURN            91..96
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   STRAND          98..105
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   HELIX           110..123
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   STRAND          128..132
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   HELIX           136..145
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   HELIX           146..149
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   STRAND          152..157
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   HELIX           161..164
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   TURN            166..168
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   STRAND          172..176
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   HELIX           179..181
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   HELIX           182..192
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   STRAND          197..205
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   HELIX           206..219
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   TURN            220..223
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   STRAND          225..234
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   HELIX           237..245
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   STRAND          250..254
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   HELIX           257..269
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   STRAND          274..276
FT                   /evidence="ECO:0007744|PDB:6WIV"
FT   STRAND          278..283
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   TURN            287..290
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   HELIX           304..311
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   STRAND          315..319
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   HELIX           335..345
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   TURN            346..348
FT                   /evidence="ECO:0007744|PDB:4MR7"
FT   HELIX           355..372
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   HELIX           378..387
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   HELIX           393..404
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   STRAND          407..410
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   STRAND          413..418
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   STRAND          421..423
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   STRAND          425..431
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   STRAND          436..443
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   TURN            444..447
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   STRAND          448..451
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   TURN            453..455
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   STRAND          459..462
FT                   /evidence="ECO:0007744|PDB:4MS4"
FT   STRAND          470..474
FT                   /evidence="ECO:0007744|PDB:7C7Q"
FT   HELIX           479..505
FT                   /evidence="ECO:0007744|PDB:7C7S"
FT   TURN            506..508
FT                   /evidence="ECO:0007744|PDB:7C7S"
FT   HELIX           510..513
FT                   /evidence="ECO:0007744|PDB:7C7S"
FT   HELIX           517..538
FT                   /evidence="ECO:0007744|PDB:7C7S"
FT   STRAND          541..544
FT                   /evidence="ECO:0007744|PDB:7C7S"
FT   HELIX           546..550
FT                   /evidence="ECO:0007744|PDB:7C7S"
FT   HELIX           553..583
FT                   /evidence="ECO:0007744|PDB:7C7S"
FT   TURN            596..598
FT                   /evidence="ECO:0007744|PDB:7C7S"
FT   HELIX           599..618
FT                   /evidence="ECO:0007744|PDB:7C7S"
FT   STRAND          622..627
FT                   /evidence="ECO:0007744|PDB:7C7S"
FT   STRAND          638..641
FT                   /evidence="ECO:0007744|PDB:7C7S"
FT   STRAND          644..649
FT                   /evidence="ECO:0007744|PDB:7C7S"
FT   HELIX           653..677
FT                   /evidence="ECO:0007744|PDB:7C7S"
FT   TURN            680..682
FT                   /evidence="ECO:0007744|PDB:7C7Q"
FT   TURN            684..686
FT                   /evidence="ECO:0007744|PDB:7C7Q"
FT   HELIX           690..712
FT                   /evidence="ECO:0007744|PDB:7C7S"
FT   HELIX           717..740
FT                   /evidence="ECO:0007744|PDB:7C7S"
FT   HELIX           742..748
FT                   /evidence="ECO:0007744|PDB:7C7S"
FT   HELIX           780..816
FT                   /evidence="ECO:0007744|PDB:4PAS"
FT   HELIX           885..890
FT                   /evidence="ECO:0007744|PDB:6M8R"
FT   HELIX           899..902
FT                   /evidence="ECO:0007744|PDB:6OCP"
FT   STRAND          908..911
FT                   /evidence="ECO:0007744|PDB:6M8R"
SQ   SEQUENCE   941 AA;  105821 MW;  09F1773DB0673C5D CRC64;
     MASPRSSGQP GPPPPPPPPP ARLLLLLLLP LLLPLAPGAW GWARGAPRPP PSSPPLSIMG
     LMPLTKEVAK GSIGRGVLPA VELAIEQIRN ESLLRPYFLD LRLYDTECDN AKGLKAFYDA
     IKYGPNHLMV FGGVCPSVTS IIAESLQGWN LVQLSFAATT PVLADKKKYP YFFRTVPSDN
     AVNPAILKLL KHYQWKRVGT LTQDVQRFSE VRNDLTGVLY GEDIEISDTE SFSNDPCTSV
     KKLKGNDVRI ILGQFDQNMA AKVFCCAYEE NMYGSKYQWI IPGWYEPSWW EQVHTEANSS
     RCLRKNLLAA MEGYIGVDFE PLSSKQIKTI SGKTPQQYER EYNNKRSGVG PSKFHGYAYD
     GIWVIAKTLQ RAMETLHASS RHQRIQDFNY TDHTLGRIIL NAMNETNFFG VTGQVVFRNG
     ERMGTIKFTQ FQDSREVKVG EYNAVADTLE IINDTIRFQG SEPPKDKTII LEQLRKISLP
     LYSILSALTI LGMIMASAFL FFNIKNRNQK LIKMSSPYMN NLIILGGMLS YASIFLFGLD
     GSFVSEKTFE TLCTVRTWIL TVGYTTAFGA MFAKTWRVHA IFKNVKMKKK IIKDQKLLVI
     VGGMLLIDLC ILICWQAVDP LRRTVEKYSM EPDPAGRDIS IRPLLEHCEN THMTIWLGIV
     YAYKGLLMLF GCFLAWETRN VSIPALNDSK YIGMSVYNVG IMCIIGAAVS FLTRDQPNVQ
     FCIVALVIIF CSTITLCLVF VPKLITLRTN PDAATQNRRF QFTQNQKKED SKTSTSVTSV
     NQASTSRLEG LQSENHRLRM KITELDKDLE EVTMQLQDTP EKTTYIKQNH YQELNDILNL
     GNFTESTDGG KAILKNHLDQ NPQLQWNTTE PSRTCKDPIE DINSPEHIQR RLSLQLPILH
     HAYLPSIGGV DASCVSPCVS PTASPRHRHV PPSFRVMVSG L
//
